2,6-dichloro-9-(3-methylphenyl)-9H-purine | 1138020-10-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2,6-dichloro-9-(3-methylphenyl)-9H-purine
• 英文别名: 2,6-dichloro-9-m-tolyl-9H-purine；2,6-dichloro-9-(3-methylphenyl)purine
• CAS: 1138020-10-6
• 化学式: C₁₂H₈Cl₂N₄
• 分子量: 279.128
• InChiKey: PNPIODMPDCGVOY-UHFFFAOYSA-N

物化性质

• 沸点：
  387.3±52.0 °C(predicted)
• 密度：
  1.52±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-9-(3-methylphenyl)-9H-purine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 sodium carbonate 作用下， 以 二氯甲烷 、 异丁酰胺 为溶剂， 反应 14.0h， 生成 5-[9-(3-Methylphenyl)-2-morpholin-4-ylpurin-6-yl]pyrazin-2-amine
  参考文献：
  名称：

  [EN] PYRAZINE SUBSTITUTED PURINES
  [FR] PURINES SUBSTITUÉES PAR LA PYRAZINE

  摘要：

  本发明涉及式（I）的嘌呤化合物，其作为激酶抑制剂具有用途。更具体地，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的制药组合物以及这些化合物在治疗增殖性疾病或紊乱方面的用途。这些化合物可以作为药物用于治疗许多增殖性疾病或紊乱，包括肿瘤和癌症以及与PI3K和/或mTOR激酶相关或相关的其他紊乱或疾病。

  公开号：

  WO2009157880A1
• 作为产物：
  描述：

  3-甲基苯硼酸 、 2,6-二氯嘌呤 在 copper diacetate 、 苯并[c][1,8]萘啶 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以50%的产率得到2,6-dichloro-9-(3-methylphenyl)-9H-purine
  参考文献：
  名称：

  [EN] 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K
  [FR] 2 -MORPHOLINYLPURINES EN TANT QU'INHIBITEURS DE PI3K

  摘要：

  本发明涉及作为激酶抑制剂有用的嘌呤化合物。更具体地说，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的药物组合物以及在治疗增殖性疾病中使用这些化合物的用途。这些化合物可能作为药物用于治疗多种增殖性疾病，包括肿瘤和癌症以及与mTOR激酶相关的其他疾病或症状。

  公开号：

  WO2009045174A1

文献信息

• [EN] 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K<br/>[FR] 2 -MORPHOLINYLPURINES EN TANT QU'INHIBITEURS DE PI3K
  申请人：S BIO PTE LTD

  公开号：WO2009045174A1

  公开（公告）日：2009-04-09

  The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with mTOR kinases.

  本发明涉及作为激酶抑制剂有用的嘌呤化合物。更具体地说，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的药物组合物以及在治疗增殖性疾病中使用这些化合物的用途。这些化合物可能作为药物用于治疗多种增殖性疾病，包括肿瘤和癌症以及与mTOR激酶相关的其他疾病或症状。
• PYRAZINE SUBSTITUTED PURINES
  申请人：Nagaraj Harish Kumar Mysore

  公开号：US20110105500A1

  公开（公告）日：2011-05-05

  The present invention relates to purine compounds of formula (I) that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3K and/or mTOR kinases.

  本发明涉及公式(I)的嘌呤化合物，其作为激酶抑制剂具有用途。更具体地，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的制药组合物以及在治疗增殖性疾病或疾病方面使用这些化合物的用途。这些化合物可用作药物治疗多种增殖性疾病或疾病，包括肿瘤和癌症，以及与PI3K和/或mTOR激酶相关或相关的其他疾病或状况。
• Pyrimidine substituted purine derivatives
  申请人：Verastem

  公开号：US08247410B2

  公开（公告）日：2012-08-21

  The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumors and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.

  本发明涉及用作激酶抑制剂的嘌呤化合物。更具体地，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的制药组合物以及这些化合物在治疗增殖性疾病或疾病方面的用途。这些化合物可能有用作药物治疗许多增殖性疾病或疾病，包括肿瘤和癌症以及与PI3和/或mTOR激酶相关或相关的其他疾病或病况。
• PYRIMIDINE SUBSTITUTED PURINE DERIVATIVES
  申请人：VERASTEM, INC.

  公开号：US20140066620A1

  公开（公告）日：2014-03-06

  The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.

  本发明涉及用作激酶抑制剂的嘌呤化合物。更具体地，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的制药组合物以及这些化合物在治疗增殖性疾病或疾病方面的用途。这些化合物可能作为药物用于治疗多种增殖性疾病或疾病，包括肿瘤和癌症以及与PI3和/或mTOR激酶有关或相关的其他疾病或疾病。
• 2-MORPHOLINYLPURINES AS INHIBITORS OF PI3K
  申请人：Nagaraj Harish Kumar Mysore

  公开号：US20110009403A1

  公开（公告）日：2011-01-13

  The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with mTOR kinases.

  本发明涉及嘌呤化合物，可用作激酶抑制剂。更具体地说，本发明涉及嘌呤化合物、其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗增殖性疾病方面的用途。这些化合物可以作为药物治疗多种增殖性疾病，包括肿瘤和癌症以及与mTOR激酶相关或相关的其他疾病或病况。